IN8bio reports Q2 2026 net loss of $4.8M; advances gamma-delta TCE platform with in vivo data expected H2 2026

IN8BIO, INC.

Net loss of $4.8M ($0.25 per share) in Q2 2026, improved from $5.1M ($1.24) in Q2 2025.
Cash of $18.0M at June 30, 2026, up from $13.2M a year earlier.
DeltEx DRI in GBM: mOS >19.5 months, mPFS 13.0 months vs 6.6 months SOC.
INB-619 gamma-delta TCE platform advancing; initial in vivo data expected H2 2026.
Peer-reviewed publication in JCO and updated data at ASCO 2026 for DeltEx DRI in GBM.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.